Research Use Only - Not for human consumption. 18+ only.
Clinical TrialsGrowth Hormone SecretagoguesSubcutaneous

GHRP-1

First-generation growth hormone releasing peptide that stimulates GH secretion through ghrelin receptor agonism. Moderate potency compared to later GHRPs. Used primarily in research settings to investigate GH dynamics and metabolic effects.

Research Status

Clinical Trials

Limited Clinical Data

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Stimulates growth hormone release
Supports lean muscle preservation
Enhances recovery from exercise
Promotes fat metabolism
Improves sleep quality

Side Effects

Increased appetite
CommonMild

Ghrelin receptor activation stimulates appetite. Typically resolves within hours post-injection. Manage by timing injections away from meals if appetite suppression is desired.

Transient cortisol elevation
CommonMild

GHRP-1 can transiently increase cortisol levels. Clinically insignificant in most cases but may be relevant for individuals with cortisol sensitivity.

Injection site reactions
UncommonMild

Redness, itching, or mild swelling at injection site. Prevent through proper site rotation and sterile technique. Usually resolves within hours.

Flushing or facial redness
UncommonMild

Transient vasodilation may occur post-injection. Typically mild and self-resolving within 10-30 minutes.

Headache
UncommonMild

Reported in some users, possibly related to rapid GH elevation or cortisol response. Usually mild and transient.

Tachyphylaxis (reduced response over time)
CommonModerate

Repeated daily dosing leads to diminished GH response within 2-4 weeks. Mitigate by cycling: 5 days on, 2 days off, or alternating with other secretagogues.

Carpal tunnel syndrome symptoms
RareModerate

Chronic GH elevation can cause fluid retention and nerve compression. Rare at research doses but documented with long-term use. Discontinue if symptoms develop.

Hyperglycemia
RareModerate

GH is diabetogenic; individuals with insulin resistance or diabetes risk may experience elevated blood glucose. Monitor fasting glucose if using chronically.

Joint or muscle pain
UncommonMild

Reported anecdotally; may relate to rapid GH elevation or fluid retention. Usually resolves with continued use or dose reduction.

Dosing Reference

ParameterValue
Dose range100-300 mcg
Frequency1-3x daily
TimingBefore bed, before meals, or post-exercise
RouteSubcutaneous

Research compound. Start at 100 mcg and titrate based on response. Fasting state enhances GH release. Timing relative to meals and exercise significantly affects efficacy.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Molecular weight817.95
Half-life30-60 minutes (plasma); GH response peaks 30-60 minutes post-injection
SequenceHis-D-Trp-Ala-Trp-D-Phe-Lys-NH2

GHRP-1 is a synthetic hexapeptide that acts as a ghrelin receptor (GHS-R1a) agonist, stimulating the release of growth hormone from the anterior pituitary gland. It works synergistically with endogenous GHRH (growth hormone-releasing hormone) to amplify GH secretion. The peptide triggers calcium influx in somatotroph cells, leading to exocytosis of GH-containing granules.

Ghrelin Receptor (GHS-R1a) Activation

GHRP-1 binds to GHS-R1a on pituitary somatotroph cells, activating G-protein coupled receptor signaling that increases intracellular calcium and triggers GH release.

GHRH Potentiation

GHRP-1 enhances the effect of endogenous GHRH, creating a synergistic GH-releasing effect greater than either stimulus alone.

Somatostatin Inhibition

GHRP-1 may suppress somatostatin (GH-inhibiting hormone) secretion, removing a brake on GH release.

  • GHRP-1 is a hexapeptide with D-amino acid substitutions for metabolic stability
  • GH secretion is pulsatile; GHRP-1 induces discrete GH pulses rather than continuous elevation
  • Efficacy is reduced in fed state; fasting or low blood glucose enhances response
  • Tachyphylaxis (reduced response) can develop with continuous use; cycling protocols are recommended

Track your GHRP-1 research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. GHRP-1 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.